No Data
Hansoh Pharma (03692) has obtained clinical approval for Class 1 innovative drugs, intended to treat manic episodes in bipolar I disorder.
On July 23rd, China's National Medical Products Administration's Drug Evaluation Center website announced that two clinical applications for Class 1 New Drug HS-10380, submitted by Hansoh Pharma (03692), have been approved for the treatment of bipolar I disorder manic episodes.
Nomura Adjusts Hansoh Pharmaceutical's Price Target to HK$17.23 From HK$15.03, Keeps at Neutral
Nomura: Maintains a "neutral" rating for Hansoh Pharma (03692) and raises the target price to HKD 17.23.
Nomura estimates that Hansoh Pharma (03692) will see a 38.2% increase in revenue and an 86.1% increase in profit in the first half of the year compared to the same period last year.
HK stocks alert | Hansoh Pharma (03692) rises over 3%. The domestic market application for indication adaptation of Alimta for lung cancer adjuvant therapy has been accepted.
Hansoh Pharma (03692) rose more than 3%. As of the time of writing, it rose 3.24% to HKD 17.80, with a turnover of 23.7771 million Hong Kong dollars.
Chinese Drug Regulator Accepts Hansoh Pharmaceutical's NDA for Cancer Adjuvant Therapy Drug
Hansoh Pharma (03692.HK): The application for marketing approval for the use of Amel in the adjuvant treatment of non-small cell lung cancer with EGFR mutations has been accepted by the National Medical Products Administration.
Hansoh Pharma (03692.HK) announced on July 19 that the Type 1 innovative drug, Amele, developed by its subsidiary, Jiangsu Haosen Pharmaceutical Group Co., Ltd., has applied for market approval for the adjuvant treatment of tumor resection in adult patients with non-small cell lung cancer (NSCLC) carrying the exon 19 deletion or exon 21 (L858R) substitution mutation of epidermal growth factor receptor (EGFR) and tested positive. This application is Amele's third indication and has been accepted by the China National Medical Products Administration.
Optimistic Investors Push Hansoh Pharmaceutical Group Company Limited (HKG:3692) Shares Up 28% But Growth Is LackingNo Data
